Portal hypertension & cirrhosis,
Год журнала:
2023,
Номер
2(2), С. 61 - 77
Опубликована: Июнь 1, 2023
Abstract
Aims
Patients
with
liver
disease
may
exhibit
higher
infection
rates
and
mortality
from
coronavirus
2019
(COVID‐19)
than
healthy
individuals,
vaccination
against
severe
acute
respiratory
syndrome
2
(SARS‐CoV‐2)
is
an
effective
prevention
strategy.
This
meta‐analysis
aimed
to
assess
the
effectiveness
safety
of
SARS‐CoV‐2
vaccines
in
patients
chronic
(CLD)
post‐liver
transplantation
(LT).
Methods
The
PubMed,
Embase,
Cochrane
databases
were
searched.
A
random‐effects
model
was
used
determine
seropositivity
antibodies,
odds
ratio
(OR)
compared
controls
(HC),
risk
(RR)
between
booster
standard
regimen,
rate
adverse
reactions
(ADR).
Results
In
regimen
analysis,
17
controlled
articles
included
for
six
ADR
analysis.
pooled
antibodies
CLD
post‐LT
93.3%
(95%
confidence
interval
[CI]:
89.0%–97.6%)
69.1%
CI:
63.0%–75.3%),
respectively.
Both
lower
those
HC
(
p
<
0.001).
differences
remained
significant
after
sorting
by
detection
interval,
vaccine
type,
antibody
or
type.
LT
recipients
showed
much
(69.1%
vs.
93.3%)
(OR:
0.055).
total
24.0%
16.2%–31.8%).
11
prospective
studies
enrolled,
dose
increased
27%
(RR:
1.27,
95%
1.15–1.41,
Conclusion
can
gain
protection
COVID‐19
vaccines,
demonstrating
a
potentially
weaker
immunogenic
response
HC.
Booster
compensate
this
deficiency.
Therefore,
should
be
prioritized
receiving
vaccine.
EBioMedicine,
Год журнала:
2023,
Номер
99, С. 104912 - 104912
Опубликована: Дек. 13, 2023
Abnormal
liver
function
was
frequently
observed
in
nonalcoholic
fatty
disease
(NAFLD)
patients
infected
with
SARS-CoV-2.
Our
aim
to
explore
the
effect
of
SARS-CoV-2
inactivated
vaccines
on
abnormality
among
NAFLD
COVID-19.
Human Vaccines & Immunotherapeutics,
Год журнала:
2024,
Номер
20(1)
Опубликована: Март 11, 2024
The
immunogenicity
of
COVID-19
vaccines
in
patients
with
liver
cirrhosis
remains
largely
unknown.
purpose
this
meta-analysis
was
to
investigate
the
and
compare
humoral
cellular
immune
responses
following
complete
vaccination
between
healthy
controls.
A
systematic
literature
search
conducted
PubMed,
EMBASE,
Web
Science
from
1
January
2020
22
August
2023.
Sixteen
studies
2127
were
included.
pooled
seroconversion
rate
92.4%
(95%
CI,
86.2%–96%,
I2
=
90%)
significant
between-study
heterogeneity.
Moreover,
elicited
a
higher
response
compensated
as
compared
decompensated
(RR
1.069,
95%
1.011–1.131,
17%,
p
.019).
Additionally,
10
included
for
comparison
analysis
results
showed
that
slightly
lower
controls
0.972,
0.955–0.989,
66%,
.001).
Meanwhile,
RR
vs.
0.678
0.563–0.817,
0,
<
.0001).
Our
demonstrated
diminished
cirrhosis.
Patients
particularly
who
have
completed
full-doses
should
receive
continuous
attention
preemptive
measures.
Frontiers in Immunology,
Год журнала:
2023,
Номер
14
Опубликована: Янв. 18, 2023
The
neutralizing
antibodies
(NAbs)
response
after
COVID-19
vaccination
liver
dysfunction
is
unclear.
In
this
study,
we
evaluated
the
NAbs
in
hospitalized
patients
suffering
from
dysfunction.
cross-sectional
study
with
longitudinal
follow-up,
enrolled
eligible
and
healthy
volunteers
full-course
vaccination.
Blood
samples
were
collected
for
testing
at
time
of
admission
treatment.
Multiple
regression
analysis
to
assess
independent
risk
factors
affecting
response.
A
total
137
134
controls
(HC)
enrolled.
Both
seropositivity
(65.7%
vs
80.6%,
p<0.01)
titer
(3.95
4.94
log2
AU/ml,
p<0.001)
significantly
lower
than
that
HC.
decrease
antibody
was
faster
After
adjusting
potential
confounding
factors,
males
(odds
ratio
[OR]:
0.17;
95%
confidence
interval
[CI]:
0.06,
0.46;
severe
damage
(OR:
0.30;
CI:
0.12,
0.71;
associated
reduction
probability
multiple
analysis.
Males
(β
=-1.18;
-1.73,-0.64)
chronic
diseases
=-1.45;
-2.13,
-0.76)
titers.
26
failure,
both
(53.8%
84.6%,
p<0.05)
(3.55
4.32
did
not
but
increased
artificial
plasmapheresis.
inactivated
or
subunit
recombinant
vaccines
waning
Moreover,
male
sex,
injury
have
an
poor
responses.
Frontiers in Immunology,
Год журнала:
2023,
Номер
14
Опубликована: Июнь 15, 2023
Aim
The
present
study
aimed
to
evaluate
the
durability
of
immune
response
after
basic
and
booster
immunization
with
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
vaccines
in
patients
chronic
liver
disease
(CLD).
Methods
Patients
CLD
complete
or
SARS-CoV-2
were
included
this
study.
Based
on
vaccination
situation,
they
divided
into
immunity
group
(Basic)
(Booster),
which
then
subdivided
four
groups
according
time
interval
from
completion
serological
specimen
collection.
positive
rates
antibody
titers
novel
neutralizing
(nCoV
NTAb)
spike
receptor-binding
domain
S-RBD)
analyzed.
Results
A
total
313
enrolled
study,
including
201
Basic
112
Booster.
nCoV
NTAb
S-RBD
within
30
days
completing
80.4%
84.8%,
respectively,
but
decreased
rapidly
extension
time,
only
29%
48.4%
remained
for
S-RBD,
120
immunization.
Within
immunization,
increased
29.0%
at
end
95.2%
90.5%,
maintained
a
high
level
(defined
as
rate
>50%)
until
when
still
79.5%
87.2%,
respectively.
After
turn
negative
was
169
days,
significantly
prolonged
266
329
Conclusion
It
is
safe
effective
vaccines.
further
improved
prolonged.
Virologica Sinica,
Год журнала:
2023,
Номер
38(5), С. 723 - 734
Опубликована: Июль 22, 2023
Chronic
liver
disease
(CLD)
entails
elevated
risk
of
COVID-19
severity
and
mortality.
The
effectiveness
the
booster
dose
inactivated
SARS-CoV-2
vaccine
in
stimulating
antibody
response
CLD
patients
is
unclear.
Therefore,
we
conducted
a
cross-sectional
study
involving
237
adult
170
healthy
controls
(HC)
to
analyze
neutralizing
antibodies
(NAbs)
against
prototype
BA.4/5
variant,
anti-receptor
binding
domain
(RBD)
IgG,
total
anti-SARS-CoV-2
antibodies.
Serum
levels
antibodies,
anti-RBD
IgG
inhibition
efficacy
NAbs
were
significantly
after
compared
with
pre-booster
dose,
but
relatively
lower
than
those
HCs.
Induced
humoral
responses
decreased
over
time
vaccination.
neutralization
efficiency
serum
increased
remained
below
threshold.
All
four
including
BA.4/5,
severe
non-severe
CLD.
After
shot,
age
last
factors
for
seropositivity
NAb
patients.
Additionally,
white
blood
cell
counts
hepatitis
B
core
protective
factors,
was
factor
associated
Overall,
our
data
uncovered
that
improved
peaked
at
120
days
vaccines.
excepting
declined
peak.
exhibited
impaired
immunologic
vaccination
weakened
which
hindered
effect
shot
Omicron
prevalence.
Cellular
immune
should
be
further
evaluated
determine
optimal
regimen
Vaccines,
Год журнала:
2023,
Номер
11(8), С. 1293 - 1293
Опубликована: Июль 28, 2023
Chronic
liver
disease
(CLD)
patients
have
higher
mortality
and
hospitalization
rates
after
infection
with
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2).
This
study
aimed
to
explore
SARS-CoV-2
vaccine
perceptions,
side
effects,
factors
associated
nonvaccination
attitudes
toward
fourth-dose
among
CLD
patients.
The
differences
between
vaccinated
unvaccinated
groups
1491
the
risk
status
were
analyzed.
In
total,
1239
immunized
against
SARS-CoV-2.
a
high
level
of
trust
in
government
clinicians
likely
follow
their
recommendations
for
vaccination.
Reasons
reported
mainly
concerns
about
vaccines
affecting
ongoing
treatments
fear
adverse
events.
However,
only
4.84%
mild
effects.
Risk
influencing
included
being
older
age,
having
cirrhosis,
receiving
treatments,
no
knowledge
considerations
not
doctors'
positive
advice
on
Furthermore,
20.6%
completely
participants
refused
fourth
dose
because
they
concerned
effects
believed
that
complete
was
sufficiently
protective.
Our
proved
safe
findings
suggest
governments
health
workers
should
provide
more
vaccination
information
customize
strategies
improve
coverage
enhance
protection
population.
Expert Review of Vaccines,
Год журнала:
2023,
Номер
22(1), С. 1102 - 1113
Опубликована: Окт. 25, 2023
Research
on
immunogenicity
after
3rd
SARS-CoV-2
vaccine
in
elder
hepatocellular
carcinoma
(HCC)
was
limited.
This
study
aimed
to
investigate
the
efficacy
and
influencing
factors
of
inactivated
HCC.We
assessed
total
antibodies,
anti-RBD
IgG,
neutralizing
antibodies
(NAb)
toward
wild
type
(WT)
as
well
BA.4/5
304
uninfected
HCC,
147
matched
healthy
control
(HC),
53
infected
all
aged
over
60
years.
The
levels
were
compared
period
7-90,
91-180,
>180
days
2nd
or
vaccination,
respectively.HCC
had
lower
seropositivity
than
HC
dose
(total
64%
vs.
92%,
P
<
0.0001;
50%
77%,
0.0001).
But
can
efficaciously
close
gap
96%
100%,
=
0.1212;
IgG:
87%
87%,
>
0.9999).
Booster
effect
persist
HCC
(2nd
3rd:
0.60
3.20,
13.86
68.85,
WT
NAb,
11.70
22.47,
Vaccinated
more
evident
humoral
responses
unvaccinated
ones
infection
antibodies:
3.85
910.92
NAb:
96.09
86.53
5.59,
0.0001).Our
findings
highlight
booster
protective
role
dose.
Our
results
could
provide
a
theoretical
foundation
for
informing
decisions
regarding
vaccination
HCC.
GE Portuguese Journal of Gastroenterology,
Год журнала:
2023,
Номер
31(5), С. 325 - 337
Опубликована: Ноя. 15, 2023
Three
years
after
the
beginning
of
SARS-CoV-2
pandemic,
safety
and
efficacy
COVID-19
vaccination
in
liver
cirrhosis
(LC)
patients
remain
controversial.
We
aimed
to
study
safety,
immunological,
clinical
responses
LC
vaccination.
Clinical and Experimental Vaccine Research,
Год журнала:
2024,
Номер
13(2), С. 83 - 83
Опубликована: Янв. 1, 2024
The
emergence
of
coronavirus
disease
2019
(COVID-19)
vaccines
has
been
a
remarkable
advancement.
However,
the
efficacy,
immunogenicity,
and
safety
these
in
individuals
with
liver
cirrhosis
require
careful
evaluation
due
to
their
compromised
immune
status
potential
interactions
underlying
disease.
present
study
aimed
evaluate
efficacy
COVID-19
patients.
In
study,
we
searched
international
databases,
including
Google
Scholar,
PubMed,
Scopus,
Embase,
Web
Science.
search
strategy
was
carried
out
by
using
keywords
MeSH
(Medical
Subject
Headings)
terms.
STATA
ver.
15.0
(Stata
Corp.,
USA)
used
analyze
data
statistically.
analysis
performed
random-effects
model.
We
also
chi-square
test
I
